21. October 2011 12:31
Amgen has appointed Tony Hooper as its new Executive Vice President of Global Commercial Operations.
The 56-year-old joins from Bristol-Myers Squibb and will take on the responsibility for the companies commercial operations around the globe.
Robert Bradway, President and Chief Operating Officer, says Mr Hooper’s “passion for serving patients across the globe make him an outstanding addition”.
He joins after 16 years at BMS where he led the commercial business in the US, Asia, Middle East, Africa, South America and Europe. Most recently he served as the Senior Vice President, Commercial Operations and President, United States, Japan and Intercontinental.
“It's a privilege to join Amgen, a Company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses,” said Mr Hooper. “I am looking forward to bringing my global commercial experience to Amgen as it moves to implement its strategic vision for growth and international expansion.”
On the same day at Hooper’s appointment, Amgen decided to cut 380 R&D jobs.
14. October 2011 12:47
Amgen has appointed Robert A. Bradway to the company’s Board of Directors.
The current President and Chief Operating Officer’s addition takes the number of board members to 13.
Mr Bradway joined the biotechnology company back in five years ago as Vice President, Operations Strategy before moving to Vice President and Chief Financial Officer from April 2007 to May 2010.
Prior to joining Amgen, he served as managing director at Morgan Stanley in London where he was responsible for banking department and corporate finance activities in Europe for the firm.
He also currently serves on the board of directors of Norfolk Southern Corporation.
4. October 2011 11:59
Roche and Diagnostica Stago’s partnership to collaborate to market Stago’s products has been terminated, with the exception of distributions in Japan.
As of the end of 2011, Roche will stop selling Stago’s products, ending their long-term collaboration in the business of Laboratory Coagulation.
Bertrand Bonnot, COO of Stago, said: “We are convinced that, after almost 40 years of successful partnership, it is the right timing for both companies to follow independent paths. Nevertheless, both Stago and Roche are committed to work together to ensure a seamless transition in the coming years.”
However, Roche Diagnostics Japan will continue to distribute Stago’s portfolio within the Japanese market under a separate agreement.
Stago will instead sell its products directly or through other distribution channels.
Stago is an IVD company based in Paris, which develops and markets reagents and automated systems for the investigation of blood coagulation disorders, with a focus in haemostasis.
Switzerland-based Roche is a leader in research-based healthcare with strengths in pharmaceuticals and diagnostics.